Amicus Therapeutics

Showing 6 posts of 6 posts found.

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

john_crowley_edit

John Crowley speaks on drug development and the FDA

May 24, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amicus Therapeutics, John Crowley, biotech, drugs, pharma, pharmaceutical

Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.

fda2outsideweb

Plot twist as FDA U-turns on Amicus drug decision

July 11, 2017
Research and Development, Sales and Marketing Amicus Therapeutics, FDA, Galafold

The news continues to flow out of the FDA, as it grabs another headline by backtracking on its previous decision …

Amicus Therapeutics’ Fabry disease drug gets European regulatory support

April 4, 2016
Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease

Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …

GlaxoSmithKline

GSK-Amicus start late-stage trials of Fabry disease treatment

September 14, 2011
Research and Development Amicus Therapeutics, Fabry disease, GSK

GlaxoSmithKline and Amicus Therapeutics are moving forward with their phase III programme for Fabry disease treatment Amigal. The first patient …

GSK signs rare diseases deal with Amicus

November 1, 2010
Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …

Latest content